Turnstone Biologics (TSBX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TSBX Turnstone Biologics

Watchlist

0.480
-0.002-0.41%

Close Dec 13 16:00 ET

11.10MMarket Cap-0.15P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Turnstone Biologics Corp : BofA Global Research Cuts Price Objective to $0.40 From $0.50
ReutersNov 15 09:47 ET
BofA Securities Downgrades Turnstone Biologics(TSBX.US) to Sell Rating, Cuts Target Price to $0.4
Moomoo NewsNov 15 06:31 ET · Ratings
Turnstone Biologics Downgraded to Underperform From Neutral at BofA
TipRanksNov 15 06:11 ET · Ratings
Leerink Partners Maintains Turnstone Biologics(TSBX.US) With Hold Rating
Moomoo NewsNov 14 03:32 ET · Ratings
Turnstone Biologics Faces Financial and Operational Challenges
TipRanksNov 12 23:53 ET
Turnstone Biologics | 10-Q: Q3 2024 Earnings Report
SECNov 12 16:31 ET · Announcements

Comments

Bellaah

Nov 6 12:25

$Turnstone Biologics (TSBX.US)$ 2

Jaguar8

Nov 5 08:02

NEWS

$Turnstone Biologics (TSBX.US)$
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone Biologics (NASDAQ: TSBX)presented preclinical data on their Selected TIL technology at the 2024 SITC Annual Meeting. The research focuses on selectively expanding tumor-reactive T cells for solid tumor treatment. Two key studies were presented...

Iwanttolive

Aug 15 09:22

$Turnstone Biologics (TSBX.US)$ why falling like this

Jaguar8

Aug 14 15:41

Look at that. Good Trial result and not so bad ER, and just went waterfall 😂

$Turnstone Biologics (TSBX.US)$

Jaguar8

Aug 14 15:06

Added NEWS ER

$Turnstone Biologics (TSBX.US)$
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Corp. (Nasdaq: TSBX) reported Q2 2024 financial results and business highlights. Key points include:
1. Positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer, with a 25% overall response rate and 50% disease control rate.
2. Cash position of $62.4 million, expected to fund operations into Q...

Heat List

Overall

No Data